

ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1371
PUBLICATION NUMBER

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2094295

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

The document provided hereafter was filed at "The Patent Office" in England under the law CAP.266 before the 1st of April 1998. It was published afterwards by the UK patent office only in English.

(12)UK Patent Application (19)GB (11) 2 094 295 A

(21) Application No 8202948
(22) Date of filing
2 Feb 1982
(30) Priority data
(31) 241317
(32) 6 Mar 1981
(33) United States of America (US)
(43) Application published
15 Sep 1982
(51) INT CL³ C07D 405/00 A61K 31/33 C07D 239/72
(52) Domestic classification
C2C 1300 1604 213 215 220 226 227 22Y 234 240 246 247 250 252 253 25Y 28X 305 30Y 313 31Y 321 32Y 332 338 339 351 355 35Y 364 365 366 368 36Y 388 389 401 40Y 470 471 491 500 509 50Y 620 621 623 624 625 628 633 634 644 658 660 661 662 665 66X 672 699 774 777 778 802 80Y AA BY LM MK UQ UR WA WE
(56) Documents cited
None
(58) Field of search
C2C
(71) Applicant
Bristol-Myers Company
345 Park Avenue
New York 10154
United States of America
(72) Inventors
William E Kreighbaum
William T Comer
(74) Agents
Carpmaels and Ransford
43 Bloomsbury Square
London WC1A 2RA

(54) **Anti-tumor quinazoline compounds**

(57) 6 and/or 7-(oxiranylmethoxy)-quinazolines of the formula:–



I

wherein one of R^6 and R^7 is oxiranylmethyl and the other is methyl or oxiranylmethyl and R^2 and R^4 are hydrogen atoms or various substituents, have potent *anti-tumor* activity in animals.

GB 2 094 295 A

SPECIFICATION

Anti-tumor quinazoline compounds

4-Ethyl-6-methoxy-7-(oxiranylmethoxy)quinazoline and its isomer 4-ethyl-7-methoxy-6-(oxiranylmethoxy)quinazoline have potent anti-tumor activity in animals.

Field of the Invention

The invention is concerned with heterocyclic carbon compounds of the quinazoline series (Class 544, Subclass 253) having oxirane-containing substituent groups.

Description of the Prior Art

The following are referred to as representatives of cytostatic compounds known in the prior art which bear the oxirane substituent. None of these is believed to be structurally related to the present compounds in such a way as to raise a presumption of obviousness. The Derwent Publications, Ltd., London WC1X 8RP England, Farmdoc Accession Numbers relative to the abstracts of the patents cited are used for reference purposes.

Derwent No. 29,765, South African 67/3220 published September 29, 1967, 5,5-Dimethyl-1,3-di(oxiranylmethyl)imidazolidine-2,4-dione is useful as an antitumor agent.

Derwent No. 46879 W/28, Japan 50030890 23 published March 27, 1975, 5-Fluoro-1-(oxiranylmethyl)-2,4-(1*H*,3*H*)pyrimidindione has anti-carcinogenic activity.

Belgian 844,136 published November 3, 1976, (Derwent No. 88859 X/48) 5-Fluoro-2-(oxiranylmethoxy)-4-oxopyrimidine is alleged to be a low toxicity anti-tumor agent.

Quinazoline compounds, also structurally unrelated to the present substances, have been reported to possess anti-tumor activity. The following are illustrative.

Belgium 773,818 (Derwent No. 25523Y), published April 12, 1972, Quinazolone diurethanes such as 3-methyl-6-(methoxycarbonylamino)-2-[3-(methoxycarbonylamino)phenyl]quinazolin-4(3*H*)-one are effective against the mouse L1210 leukemia, pages 1, 7, 8, 9, 10, and 21.

U.S. Patent No. 3,455,920 patented July 15, 1969 (Derwent No. 38866), 6-Nitro-2-phenyl-1,2,3,4-tetrahydroquinazolin-4-one exhibits cytotoxic activity *in vivo* against the Walker 256 carcinoma in mice.

Numerous entries appear in Chemical Abstracts Formula Index under the molecular formula $C_{11}H_{10}N_2O_2$ which corresponds to the quinazoline ring substituted by the (2-oxiranyl)methoxy group, but no compound is indexed having the (2-oxiranyl)methoxy group attached to the quinazoline ring. The most closely related compound of this formula which is reported is 3-[(2-oxiranyl)methyl]-1,4-dihydro-(4*H*)-quinazolin-4-one, which structure differs in a number of significant respects from the present compounds.

Summary of the Invention

This invention is concerned with quinazoline compounds having the following structural formula



I

In Formula I at least one of R^6 and R^7 is the oxiranylmethyl group and the other is methyl or a second oxiranylmethyl group. R^2 and R^4 are independently selected from hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, substituted phenyl, phenylalkyl having up to 8 carbon atoms, substituted phenylalkyl having up to 8 carbon atoms apart from the substituents. The substituents of the substituted phenyl and substituted phenylalkyl groups are ring attached and there may be one or two of them. They are selected from halogen including chlorine, bromine, iodine, and fluorine, methyl, or methoxy groups.

The compounds of Formula I are described in Procedures 3 and 4 hereof, namely, those wherein R^2 is hydrogen, R^4 is ethyl, and one of R^6 and R^7 is oxiranylmethyl and the other is methyl, have utility as intermediates in the preparation of antihypertensive agents as described in our prior co-pending U.S. application Serial No. 011,819. These compounds also have antithrombogenic, hypotensive, ileal relaxant, and smooth muscle relaxant activity, the latter similar to that exhibited by bronchodilator agents. The compound of Procedure 4 inhibits the passive cutaneous anaphylaxis reaction in the rat suggestive of anti-allergy activity.

The quinazoline compounds of this invention have antitumor activity against transplanted animal tumors of established utility for the screening of anticancer agents. The tumors against

which the present substances are active include the ascitic tumors P338 and L1210 leukemia which are widely used for primary screening and the B16 melanoma and Lewis Lung carcinoma which are used in secondary screening. A review of the screening strategy with an enumeration of the transplanted animal tumors employed has been published by William T. Bradner in Cancer and Chemotherapy, Vol. 1, pages 221–227 (1980).

Generally, the screening method involves administering a standardized tumor innoculum by intraperitoneal injection to the test animals arranged into groups to which various doses of test compound are administered by intraperitoneal injection, and median survival times in days for the various groups are determined. The results are then expressed as the percent T/C which is the ratio of the median survival time (MST) for the group of treated animals to the MST of the untreated control animals multiplied by 100. Any compound exhibiting a percent T/C≥125 is considered to have significant antitumor activity. Various dosage schedules may be employed such as a single dose on day 1 (d.1), three doses individually on days 1, 5, and 9 after innoculation (d.1, 5, 9), daily dosage over a period of time such as for nine days (qd.1→9), or others as may be suitable. The following results were obtained with the compounds of Procedures 3 and 4 hereof which were administered suspended in DMSO/saline or aqueous hydroxypropylcellulose.

Compound of Procedure 3
P388 Leukemia

Treatment Schedule	Dose, IP mg/kg/inj	MST Days	Effect MST % T/C	Average Weight Change, g	Survivors Day 6
d.1	150	TOX	TOX	TOX	0/6
	100	14.5	145	−1.1	6/6
	50	13.0	130	+0.3	6/6
	25	11.5	115	+1.2	6/6
d.1, 5 & 9	100	17.0	170	−2.3	6/6
	50	13.5	135	−0.4	5/6
	25	12.0	120	+0.6	6/6
	12.5	10.0	100	+1.3	6/6
qd 1→9	25	15.0	150	−0.7	6/6
	12.5	13.0	130	+0.5	6/6
	6.25	11.0	110	+0.9	6/6
	3.13	9.5	95	+2.1	6/6
	Saline	10.0	–	+2.6	10/10

Tumor inoculum : 10^6 ascites cells implanted i.p.
Host : CDF_1 ♀ mice.
TOX : <4/6 mice alive on Day 6

Compound of Procedure 4
P388 Leukemia

Treament Schedule	Dose, IP mg/kg	MST Days	Effect MST % T/C	Average Weight Change, g	Survivors Day 5(30)
d.1	100	TOX	TOX	−3.7	2/4
	50	12.5	139	−3.0	4/4
	25	12.0	133	−2.3	4/4
	12.5	11.0	122	−1.1	4/4

Tumor inoculum : 10^6 ascites cells implanted ip.
Host : CDF_1 ♀ mice.
TOX : <4/6 or 3/4 mice alive on Day 5.

Compound of Procedure 3
L1210 Leukemia

Treatment Schedule	Dose, IP mg/kg/inj	MST Days	Effect MST % T/C	Average Weight Change, g	Survivors Day 5
d.1	120	11.0	183	−3.7	6/6
	80	10.5	175	−2.5	6/6
	40	9.0	150	−0.9	5/6
	20	8.0	133	−1.0	5/6
d.1, 5 & 9	120	9.5	158	−3.4	4/6
	80	9.0	150	−1.0	5/5
	40	7.0	117	+0.2	5/6
	20	8.0	133	+0.2	5/6
qd 1→9	60	9.0	150	−3.2	6/6
	40	10.0	167	−2.8	6/6
	20	9.5	158	−1.1	6/6
	10	8.5	142	−0.8	6/6
	Saline	6.0	–	+1.4	10/10

Tumor inoculum : 10^6 ascites cells implanted i.p.
Host : CDF_1 ♀ mice.

Compound of Procedure 3
B16 Melanoma

Treatment Schedule	Dose, IP mg/kg/inj	MST Days	Effect MST % T/C	Average Weight Change, g	Survivors Day 10(60)
d.1, 5 & 9	120	TOX	TOX	−3.5	5/10
	80	41.0	178	−1.7	9/10 (2)*
	40	35.0	152	−0.2	10/10
	20	29.5	128	−0.3	10/10
qd 1→9	60	30.0	130	−2.4	10/10
	40	36.5	159	−2.1	10/10 (3)*
	20	36.0	156	−1.8	10/10
	10	31.0	135	−1.0	10/10
	Saline	23.0	–	+2.3	10/10

*Tumor-free at autopsy as determined by visual inspection.
Tumor inoculum : 0.5 ml of a 10% brei, ip
Host : BDF_1 ♀ mice.
TOX : <7/10 mice alive on d.10.

Compound of Procedure 3
Lewis Lung Carcinoma

Treatment Schedule	Dose, IP mg/kg/inj	MST Days	Effect MST % T/C	Average Weight Change, g	Survivors Day 10(60)
d.1, 5 & 9	80	>60.0	>400	−0.8	10/10 (6)*
	60	>60.0	>400	−0.5	10/10 (6)*
	40	20.0	133	−0.5	10/10 (4)*
qd 1→9	60	19.0	127	−2.0	8/10 (3)*
	40	>60.0	>400	−1.4	10/10 (7)*
	20	20.0	133	−0.5	10/10 (3)*
	Saline	15.0	–	−0.4	10/10

*Tumor-free.

Tumor inoculum : 10^6 tumor brei cells, ip
Host : BDF_1 ♀ mice.
TOX : <7/10 mice alive on d.10.

Detailed Description of the Invention

The compounds of the present invention are prepared by reaction of an intermediate of Formula II wherein R^2 and R^4 are as previously defined, one of R^a and R^b is hydrogen, and the other of R^a and R^b is hydrogen, or methyl, with epichlorohydrin or epibromohydrin in the presence of a base.



II

A reaction inert organic liquid reaction medium is employed at a temperature of from about 25°C up to about 150°C. Suitable bases include sodium and potassium hydroxides, alkoxides, and carbonates. Suitable reaction inert liquid organic media include ethanol, propanol, butanol, dibutyl ether, tetrahydrofuran, benzene, toluene, dimethylsulfoxide, dimethylformamide, dimethylacetamide, ethylene glycol dimethyl ether, ethylene glycol monomethyl ether, hexamethyl phosphoramide, and other alkanols, ethers, and hydrocarbons. A reaction medium in which the reactants are soluble is preferred. Use of a crown ether catalyst such as 18-crown-6 is sometimes advantageous. The preferred system employs finely powdered potassium carbonate as base in dimethylsulfoxide as reaction medium, with epibromohydrin as reactant at a reaction temperature of about 25°C. as described in Procedure 3 below.

The intermediates of Formula II are prepared by methods known in the art, for instance by catalytic debenzylation of the corresponding compound of Formula II wherein one or both of R^a and R^b is the benzyl group. The latter are produced from the corresponding alkylphenones of Formula III wherein one of R^c and R^d is benzyl and the other is methyl or benzyl.



III

Those substances of Formula III wherein R^c is benzyl and R^d is methyl are prepared from 2-methoxyphenol by conversion thereof to the chloroacetate ester, acylation thereof with an acid of the Formula R^4CO_2H in the presence of polyphosphoric acid, hydrolysis of the chloroacetate ester to yield the corresponding 1-(3-hydroxy-4-methoxyphenyl)phenone, and benzylation of the latter to yield the corresponding substances of Formula III wherein R^c is benzyl and R^d is methyl. This is illustrated in Procedure 2 below.

Those intermediates of Formula III wherein R^c is methyl, and R^d is benzyl are prepared by acylation of 2-methoxyphenol with a carboxylic acid of the formula R^4CO_2H in the fashion referred to above followed by benzylation of the corresponding 3-methoxy-4-hydroxyphenone to

yield the compound of Formula III wherein R^c is methyl, and R^d is benzyl.

The intermediates of Formula III are converted to those of Formula II by conventional means for the synthesis of quinolines such as are illustrated in U.S. Patent No. 3,248,292 patented April 26, 1966. The last step is removal of the benzyl group represented by R^c or R^d in Formula III to yield the corresponding hydroxyl compound of Formula II.

An alternative method for production of the intermediates of Formula II wherein R^a is methyl, and R^b is hydrogen or R^a and R^b are each hydrogen atoms is by hydrolysis of the corresponding compound wherein R^a and R^b are each methyl with concentrated aqueous hydrobromic acid at the reflux temperature as is illustrated in Procedures 1 and 5 hereof.

Examples

In the following procedures, temperatures are expressed in degrees centigrade (°). Melting points are corrected values according to the U.S.P. method where indicated (corr.). Abbreviations employed are MeOH (methanol), DMSO (dimethylsulfoxide), *i*-PrOH (isopropanol), abs.EtOH (absolute ethanol), EtOAc (ethyl acetate), EtOH (95% ethanol), Et_2O (diethyl ether), THF (tetrahydrofuran), MEK (2-butanone), *i*-PrOAc (isopropyl acetate), *i*-Pr_2O (di-isopropyl ether), AcOH (acetic acid), TLC (thin layer chromatography), d (decomposition). Other abbreviations have conventional established meanings.

Procedure 1. 4-ETHYL-6-METHOXYQUINAZOLIN-7-OL.- A solution of 100 g. (0.46 mole) of 4-ethyl-6,7-dimethoxyquinazoline (CAS Registry No. 4015-32-1,, m.p. 146–148°) in 250 ml. of 48% hydrobromic acid was refluxed 3.5 hrs. at which time only a trace of this starting material was evident by TLC (9:1 $CHCl_3$-MeOH; silica). The mixture was cooled to 25° and neutralized (pH 7) with concentrated NH_4OH. After the suspension had been chilled overnight (5'), the crude grey-green precipitate was collected on a filter and dried–first overnight in air and then in a vacuum oven at 50°/60 mm for 18 hrs. The dry solid (70 g., m.p. 210–215°) was recrytallized from MeOH-(*i*-$Pr)_2O$ to give 42 g. (43%) of chartreuse powder, m.p. 221–224° (uncorr.). The identity of the product was confirmed by examination of the IR spectrum.

Procedure 2. 4-ETHYL-7-METHOXYQUINAZOLIN-6-OL.- 2-Methoxyphenol was esterified by reaction with chloroacetyl chloride to give in 75% yield, 2-methoxyphenol chloroacetate, m.p. 60–61.5°. This material was acylated with propionic acid in the presence of polyphosphoric acid to produce 2-methoxy-5-propionylphenyl chloroacetate in 75% yield, m.p. 77–79.5°C. This ester was hydrolyzed with sodium acetate in methanol to yield 1-(3-hydroxy-4-methoxyphenyl)-1-propanone, m.p. 91–92°, yield 90%. Benzylation of the latter by treatment in acetone with benzyl chloride and potassium carbonate yielded 1-(3-benzyloxy-4-methoxyphenyl)-1-propanone, m.p. 83–85°, yield 96%. The latter was then nitrated by treatment with 1:3 nitric acid/acetic acid at 18–20° to yield 1-(2-nitro-4-methoxy-5-benzyloxyphenyl)-1-propanone, m.p. 120.5–123°, yield 65%. Reduction of this material with hydrazine hydrate and Raney nickel yielded 1-(2-amino-4-methoxy-5-benzyloxyphenyl)-1-propanone. The latter was cyclized by treatment with formic acid and formamide to yield 6-benzyloxy-4-ethyl-7-methoxyquinoline, yield 80%, m.p. 132–134°. Catalytic hydrogenation of the latter resulted in debenzylation to yield 4-ethyl-7-methoxyquinolin-6-ol in 85% yield, m.p. 200–202°.

Procedure 3. 7-(OXIRANYLMETHOXY)-4-ETHYL-6-METHOXYQUINAZOLINE.- A suspension of finely powdered anhyd. K_2CO_3 in 70 ml. of DMSO containing 6.2 g. (0.03 mole) of 4-ethyl-6-methoxyquinazolin-7-ol was stirred at 25° for 15 min. Epibromohydrin (10.3 g., 0.075 mole) was added in one portion and stirring was continued for 24 hrs. at 25°, after which the mixture was poured into 800 ml. H_2O and extracted twice with 200 ml. EtOAc and twice with 100 ml. CH_2Cl_2. The combined organic layers were dried (anhyd. Na_2CO_3), filtered and evaporated at 100°/60 mm to afford 13.5 g. of crude yellow solid which was recrystallized from EtOAc to give 4.75 g. of the pure intermediate, m.p. 120.0–121.0° (corr.). Elemental analysis for C, H, and N confirmed the formula $C_{14}H_{16}N_2O_3$.

Procedure 4. 6-(OXIRANYLMETHOXY)-4-ETHYL-7-METHOXYQUINAZOLINE.- 4-Ethyl-7-methoxyquinazolin-6-ol was treated as described in Procedure 3, yield 67%, m.p. 120.0–122.0° after recrystallization from EtOAc. Elemental analysis for C, H, and N confirmed the formula $C_{14}H_{16}N_2O_3$.

Procedure 5. 4-ETHYL-6,7-QUINAZOLINEDIOL.- A solution of 4-ethyl-6,7-dimethoxyquinazoline in 150 ml. of 48% HBr was refluxed for 4 hrs. and then cooled to room temperature and neutralized to pH 7 with concentrated ammonium hydroxide. The suspension was chilled overnight and the precipitate then collected on a filter and dried in the air overnight and then in a vacuum oven at 50°/60 mm for 18 hrs. The diol was then separated by fractional crystallization of 19 g. of the crude solid using first MeOH-Abs.EtOH (4:1) and then two recrystallizations from MeOH-dioxane (4:1) and a fourth crystallization from MeOH-H_2O by allowing the methanol to evaporate from the boiling solution until crystallization commenced. The diol was a yellow crystalline solid, yield 4.2 g., m.p. 277.0–278.0° (dec., corr.). Elemental analyses for carbon, hydrogen, and nitrogen corresponded to the formula $C_{10}H_{10}N_2O_2$.

Procedure 6. 6,7-DI(OXIRANYLMETHOXY)-4-ETHYLQUINAZOLINE.- 4-Ethyl-6,7-quinazoline-

diol when treated with epibromohydrin in the presence of potassium carbonate in DMSO as reaction medium according to the method of Procedure 3, the desired product is obtained.

The 6,7-dimethoxyquinazolines listed in the following table have been prepared by the method described in U.S. Patent No. 3,248,292. They are suitable for conversion according to the methods of Procedures 1 and 3 to the products of Formula I wherein R^2 and R^4 have the meanings given in the table, R^6 is methyl and R^7 is oxiranylmethyl. The corrected melting points and recrystallization solvents for the quinazoline starting materials are stated.

6,7-Dimethoxyquinazolines



No.	R^2	R^4	m.p.	Solvent	Molecular Formula
1	-H	$-CH_2CH_2CH_3$	108.5-110.5	acetonitrile	$C_{13}H_{16}N_2O_2$
2	$-CH_3$	$-CH_2CH_2CH(CH_3)_2$	90.5-91.5	heptane	$C_{16}H_{22}N_2O_2$
3	$-CH_3$	$-CH_2CH_2CH_3$	111-112.5	isopropyl	$C_{14}H_{18}N_2O_2$
4	-H	$-CH(CH_3)_2$	93-95	isopropyl	$C_{13}H_{16}N_2O_2$
5	H	H	146-148	ethyl acetate butanone	$C_{10}H_{10}N_2O_2$
6	-H	$-CH_2CH_2CH(CH_3)_2$	79.5-81.5	isopropyl ether	$C_{15}H_{20}N_2O_2$
7	$-CH_2CH_2CH_3$	$-CH_2CH_2CH_3$	157.5-159.5	ethyl acetate	$C_{16}H_{22}N_2O_2 \cdot HCl$
8	$-CH_3$	$-CH_2CH_3$	117-119	acetonitrile isopropyl ether	$C_{13}H_{16}N_2O_2$
9	-H		145-146.5	acetonitrile butanone	$C_{17}H_{14}Cl_2N_2O_2$

6,7-Dimethoxyquinazolines (continued)

No.	R^2	R^4	m.p.	Solvent	Molecular Formula
10	$-CH_3$	$-CH(CH_3)_2$	96.5-98	isopropyl ether	$C_{14}H_{18}N_2O_2$
11	H	CH_3	150-152	acetonitrile ethyl acetate	$C_{11}H_{12}N_2O_2$
12	CH_3	CH_3	112-114	acetonitrile	$C_{12}H_{14}N_2O_2$
13	H	CH_2CH_3	146-148	acetonitrile	$C_{12}H_{14}N_2O_2$
14	H		173-175	acetonitrile	$C_{16}H_{14}N_2O_2$
15	CH_3		170-172	ethyl acetate	$C_{17}H_{16}N_2O_2$
16	H		130-132	acetonitrile	$C_{17}H_{16}N_2O_2$
17	H		145-147	acetonitrile	$C_{18}H_{18}N_2O_2$
18	H		155-157	acetonitrile ethanol	$C_{17}H_{15}ClN_2O_2$
19	H		134-136	acetonitrile	$C_{18}H_{17}ClN_2O_2$
20	CH_3		166-168	acetonitrile butanone	$C_{19}H_{19}ClN_2O_2$
21	H		146-148	acetonitrile	$C_{20}H_{22}N_2O_4$
22	CH_3	H	163-165	acenotrile	$C_{11}H_{12}N_2O_2$

CLAIMS

1. A compound having Formula I



I

wherein one of R^6 and R^7 is oxiranylmethyl, and the other is methyl or oxiranylmethyl, and R^2 and R^4 are independently selected from the group consisting of hydrogen, alkyl having from 1 to 5 carbon atoms, phenyl, substituted phenyl, phenylalkyl having up to 8 carbon atoms, substituted phenylalkyl having up to 8 carbon atoms apart from the substituents, wherein said substituted phenyl and substituted phenylalkyl have one or two ring attached groups independently selected from halogen, methyl, or methoxy groups.

2. The compound of Claim 1,4-ethyl-6-methoxy-7-(oxiranylmethoxy)quinazoline.

3. The compound of Claim 1, 4-ethyl-7-methoxy-6-(oxiranylmethoxy)quinazoline.

4. A process for preparing a compound having Formula I as specified in claim 1 by reacting at a temperature of 25°C to 150°C a compound having the following Formula II



II

wherein R^2 and R^4 are as specified in claim 1, one of R^a R^b is hydrogen, and the other of R^a and R^b is hydrogen or methyl, with epichlorohydrin or epibromohydrin in the presence of a base and a reaction inert organic liquid medium, and recovering a compound of Formula I.

5. A process as claimed in claim 4 wherein the base is pulverulent potassium carbonate.

6. A process as claimed in claim 4 or 5 wherein the reaction medium is dimethyl sulfoxide.

7. A process as claimed in claim 4, 5 or 6 wherein the second-mentioned reactant is epibromohydrin.

8. A proces as claimed in claim 4, 5, 6 or 7 wherein the reactants specified are reacted at a temperature of substantially 25°C.

9. A process as claimed in any of claims 4 to 8 wherein the compound prepared is that specified in claim 2.

10. A process as claimed in any of claims 4 to 8 wherein the compound prepared is that specified in claim 3.

11. A process as claimed in claim 4, substantially as described in the foregoing Examples section.

12. A compound as claimed in claim 1, prepared by a process as claimed in any of claims 4 to 11.

13. A pharmaceutical composition comprising a compound as claimed in claim 1, 2, 3 or 12 and a pharmaceutically acceptable vehicle or carrier therefor.

14. A composition as claimed in claim 13, wherein the said compound is suspended in dimethyl sulfoxide saline or aqueous hydroxypropylcellulose.

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.—1982.
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.